On January 26, 2024 Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, reported poster presentations at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers Symposium, taking place January 25-27, 2024, in San Francisco, CA (Press release, Aadi Bioscience, JAN 26, 2024, View Source [SID1234639568]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract and poster presentation details are below:

Title: "Analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database"
Session Title: Poster Session B: Urothelial Carcinoma
Date/Time: January 26, 2024 – 11:30 – 1:00 pm; 5:45 – 6:45 pm PST
Presenting Author: Gopa Iyer, MD
Key Findings:

In a large real-world database of patients with advanced cancer, 1,828 (4.0%) of the 46,068 patients with GU cancers had at least one inactivating alteration in TSC1 or TSC2
TSC1 and/or TSC2 inactivating alterations were present in 9.2% of patients with bladder cancer, 6.4% of patients with kidney cancer, and 0.6% of patients with prostate cancer
GU cancers with TSC1 and/or TSC2 inactivating alterations were frequently microsatellite stable and of low tumor mutational burden (TMB)
The PRECISION 1 study (NCT05103358) is currently enrolling patients with solid tumors harboring TSC1 and/or TSC2 inactivating alterations
Aadi is also presenting an encore Trials-in-Progress (TiP) poster from the ongoing PRECISION 1 study.

Title: "PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2"
Session Title: Trials in Progress Poster Session C: Renal Cell Cancer: Adrenal, Penile, Urethral and Testicular Cancers
Date/Time: January 27, 2024 – 7:00 – 8:00 am; 11:30 am – 1:00 pm PST
Presenting Author: Gopa Iyer, MD

More information can be found on the ASCO (Free ASCO Whitepaper) GU meeting website.